The Democratic Republic of Congo (DRC) has reached a significant milestone in its fight against the Bundibugyo strain of Ebola, with the first patient enrolled in a clinical treatment trial aimed at identifying effective therapies for the disease.
World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus announced the development on Thursday, describing it as an important step in efforts to contain the outbreak and improve patient outcomes.
The trial comes at a critical time for the country, which is battling one of the largest outbreaks of the Bundibugyo Ebola strain ever recorded. Currently, there are no approved vaccines or treatments specifically designed for this variant of the virus.
Despite progress in expanding treatment and testing capacity, health officials warn that major obstacles remain.
Tedros highlighted a recent attack on an Ebola treatment centre in Ituri province that left two people dead, underscoring the security challenges facing health workers on the ground.
"Despite all this progress, we continue to face significant challenges, including mistrust and violence," he said.
Aid workers and health authorities have long struggled with insecurity in eastern Congo, where decades of conflict have fuelled distrust of government institutions and international organisations.
The Bundibugyo Ebola outbreak was officially declared on 15 May and has since spread across the eastern provinces of Ituri, North Kivu and South Kivu.
According to government figures released on Wednesday, the outbreak has infected 1,406 people and caused 438 deaths. The WHO said the DRC has recorded an average of 38 new confirmed cases per day over the past two weeks.
Officials are also investigating potential exposures in two additional provinces, raising concerns that the outbreak could continue to expand.
The new trial will involve more than 1,000 patients and is expected to take several months to complete.
Researchers will evaluate Mapp Biopharmaceutical's experimental antibody treatment, MBP134, both as a standalone therapy and in combination with Gilead Sciences' antiviral drug remdesivir.
The WHO said sufficient supplies of the drugs are available for the study. Discussions are also underway with the United States government, which donated MBP134 supplies, and with Gilead to ensure that patients can continue accessing the treatments if they prove safe and effective.
Gilead announced that it has donated more than 2,000 vials of remdesivir for the trial, in addition to a further 2,000 vials previously supplied for emergency use in June.
Alongside treatment efforts, global health organisations are accelerating work to develop rapid diagnostic tests for the Bundibugyo strain.
The Geneva-based diagnostics organisation FIND said five potential manufacturers have been selected from an initial pool of 21 candidates and could begin field trials in eastern Congo within weeks.
The shortlisted companies include two manufacturers from West Africa, two from South Korea and one from the United States.
Health officials say a rapid antigen test could transform outbreak control efforts by enabling medical workers to identify infected individuals immediately rather than waiting days for laboratory results.
Currently, no rapid diagnostic test has been approved for the Bundibugyo Ebola virus.
The DRC has expanded its laboratory network, now comprising 10 facilities capable of testing for Bundibugyo Ebola.
However, responders continue to face major logistical hurdles. Poor road infrastructure, unreliable electricity supplies and insecurity make it difficult to transport samples and deliver timely results.
According to the International Pandemic Preparedness Secretariat, rapid antigen tests could dramatically improve outbreak management by allowing health workers to make immediate decisions about isolation and treatment at the point of care.
FIND is also working to identify manufacturers able to provide simplified molecular tests that can be deployed in remote areas and used by laboratory personnel with limited specialist training.
The WHO says other aspects of the response are showing signs of improvement.
Authorities are now successfully following up with four out of every five identified contacts of Ebola patients. However, officials acknowledge that more contacts still need to be traced for each confirmed case.
Treatment capacity has also increased significantly. There are currently 650 Ebola treatment beds available across affected areas, with around 96% already occupied.
To cope with rising demand, the WHO and its partners are working to add another 300 beds in the coming weeks.
As the outbreak continues to spread, health officials hope that advances in treatment and diagnostics, combined with expanded healthcare capacity, will help bring the epidemic under control despite the persistent challenges posed by insecurity, limited infrastructure and public mistrust.
The U.S. has launched fresh strikes on Iran after Tehran targeted a container ship and said it had again closed the Strait of Hormuz. Iran also claime...
The 4th Shusha Global Media Forum will bring together nearly 160 media leaders, experts and officials from 54 countries in Azerbaijan's historic city...
Concerns are growing over a renewed cholera outbreak in Yemen, after years of conflict has left the country's healthcare system struggling to cope....
England captain Harry Kane scored twice and Belgium beat Senegal with a last-minute penalty as both sides joined the United States in the last 16 of the World Cup.
Canada secured a dramatic stoppage-time victory to reach the last 16, as a series of gripping World Cup matches saw Croatia, DR Congo and Argentina also progress.
Caleb Yirenkyi’s stoppage-time goal secured a 1-0 win for Ghana over Panama as World Cup action delivered a mix of late drama and key results. Colombia and England also began their campaigns with victories, while DR Congo held Portugal in a historic 1-1 draw and Austria beat Jordan 3-1.
The Ebola outbreak in DRC has spread to a new health zone in the northeastern province of Ituri, health authorities said on Wednesday (10 June), highlighting the challenges of containing the virus more than three weeks after the epidemic was declared.
U.S. President Donald Trump said Washington has agreed to resume talks with Iran after Tehran requested further negotiations, but declared that last month's ceasefire between the two countries was "over".
The 4th Shusha Global Media Forum will bring together nearly 160 media leaders, experts and officials from 54 countries in Azerbaijan's historic city of Shusha on 13-14 July, to discuss journalism’s role in peacebuilding, restoring public trust and tackling challenges.
Iran's Supreme Leader, Mojtaba Khamenei, has promised to avenge the killing of his father, while U.S. President Donald Trump said Tehran and Washington had agreed to continue talks despite an escalation of hostilities this week.
The U.S. has launched fresh strikes on Iran after Tehran targeted a container ship and said it had again closed the Strait of Hormuz. Iran also claimed to have expanded attacks on U.S. military facilities across the Gulf.
Typhoon Bavi pummelled Japan's southern Sakishima island chain with heavy rain and violent winds on Saturday as it headed towards Taiwan, prompting authorities to warn of the risks of floods and landslides.
The 4th Shusha Global Media Forum will bring together nearly 160 media leaders, experts and officials from 54 countries in Azerbaijan's historic city of Shusha on 13-14 July, to discuss journalism’s role in peacebuilding, restoring public trust and tackling challenges.
Two men were killed and six other people were injured in a shooting at Toronto's Salsa on St. Clair festival on Saturday night, police said.
Start your day informed with AnewZ Morning Brief. Here are the top news stories for the 12 July, covering the latest developments you need to know.
U.S. Senator Lindsey Graham, one of President Donald Trump’s most prominent allies in Congress, has died following a brief and sudden illness. He was 71-years-old.
Five major carmakers have largely won the first stage of a major legal battle at a High Court case brought by around 1.6 million claimants in the UK over allegations that their diesel vehicles were fitted with unlawful "defeat devices" that led to higher emissions.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment